Seattle Genetics is a biotechnology company that is focused on developing and commercializing a new generation of targeted, empowered antibody-based therapies that have the potential to change the foundation of treatment for people with cancer. Its antibody-drug conjugate (ADC) technology combines the specificity of monoclonal antibodies, innovative linker systems, and the power of potent cell-killing agents to treat cancer.
The Company also is advancing a deep pipeline of innovative therapies for blood cancers and solid tumors, including vadastuximab talirine (SGN-CD33A) an ADC in the pivotal phase 3 CASCADE clinical trial for acute myeloid leukemia (AML), enfortumab vedotin (ASG-22ME) for urothelial cancer under its collaboration with Astellas, and SGN-LIV1A for triple-negative breast cancer. Its programs are designed to address significant unmet medical needs and to improve treatment outcomes for patients.


Type
Public
HQ
Bothell, US
Founded
1998
Size (employees)
1,100 (est)+24%
Seattle Genetics was founded in 1998 and is headquartered in Bothell, US
Report incorrect company information

Key People/Management at Seattle Genetics

Clay B. Siegall

Clay B. Siegall

Co-founder, President , CEO & Chairman
Todd E. Simpson

Todd E. Simpson

CFO
Eric Dobmeier

Eric Dobmeier

Chief Operating Officer
Vaughn Himes

Vaughn Himes

EVP, Process Sciences and Technical Operations
Chris Boerner

Chris Boerner

Executive Vice President, Commercial
Jonathan Drachman

Jonathan Drachman

Chief Medical Officer; EVP, Research and Development

Seattle Genetics Office Locations

Seattle Genetics has offices in Zug and Bothell
Bothell, US (HQ)
21717 30th Dr SE
Zug, CH
19 Dammstrasse, Suite 403–406
Show all (2)
Report incorrect company information

Seattle Genetics Financials and Metrics

Seattle Genetics Financials

Seattle Genetics's revenue was reported to be $482.25 m in FY, 2017
USD

Revenue (FY, 2017)

482.3 m

Gross profit (FY, 2017)

447.5 m

Gross profit margin (FY, 2017), %

92.8%

Net income (FY, 2017)

(125.5 m)

EBIT (FY, 2017)

(195.8 m)

Market capitalization (18-Apr-2018)

7.2 b

Cash (31-Dec-2017)

160.9 m
Seattle Genetics's current market capitalization is $7.2 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

269.3 m286.8 m336.8 m418.1 m482.3 m

Revenue growth, %

6%17%24%

Cost of goods sold

13.8 m17.5 m24.5 m28.2 m34.8 m

Gross profit

255.5 m269.2 m312.3 m390 m447.5 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Revenue

71 m68.3 m68.3 m75.9 m82.2 m77.1 m84.1 m111.2 m95.4 m106.3 m109.1 m108.2 m

Cost of goods sold

3.5 m3.7 m4.1 m4.7 m5.2 m5.9 m6.6 m5.9 m6.9 m7.4 m7.5 m8.1 m

Gross profit

67.4 m64.6 m64.2 m71.1 m76.9 m71.2 m77.4 m105.2 m88.5 m98.9 m101.7 m100.2 m

Gross profit Margin, %

95%95%94%94%94%92%92%95%93%93%93%93%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

64.1 m56.9 m102.3 m108.7 m160.9 m

Accounts Receivable

29.5 m39.2 m52.9 m61.9 m84.8 m

Inventories

27.1 m43.5 m57 m68.1 m60 m

Current Assets

437.3 m408 m771.1 m734.6 m577.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

119.5 m44.8 m38.8 m50.2 m62.6 m79 m614.1 m119.5 m192.1 m131 m75.8 m197.1 m

Accounts Receivable

29.2 m37.9 m34.9 m43.8 m49.6 m45.3 m63.5 m52.4 m57.7 m65.1 m73.7 m71.9 m

Inventories

26 m29 m30.5 m37.5 m43.1 m47.5 m44.5 m60.1 m71.7 m71.6 m60.7 m69.2 m

Current Assets

435 m429.4 m423 m429.2 m396.9 m354.1 m852.8 m736.1 m750.6 m744.3 m656.2 m616 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(62.5 m)(76.1 m)(120.5 m)(140.1 m)(125.5 m)

Depreciation and Amortization

8.6 m12.5 m14.5 m18 m24.3 m

Inventories

10.7 m(16 m)(14 m)(11.2 m)8.1 m

Accounts Payable

19.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(23.7 m)(16.3 m)(17.6 m)(15.6 m)(21.7 m)(47.5 m)(26.4 m)(20.5 m)(32.7 m)(31.8 m)(60 m)

Inventories

30.5 m37.5 m43.1 m47.5 m44.5 m60.1 m71.7 m71.6 m
USDY, 2017

Revenue/Employee

511.7 k

Financial Leverage

1.3 x
Show all financial metrics

Seattle Genetics Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Cascadian Therapeutics January 31, 2018$614 m
Report incorrect company information